Published on October 7, 2009 at 1:19 AM
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that it has closed its previously announced registered direct offering of 3.97 million shares of its common stock to institutional investors at a price per share of $1.00, representing gross proceeds of $3.97 million.
The shares were offered by Catalyst pursuant to a shelf registration statement filed with the Securities and Exchange Commission that was declared effective on June 26, 2008. Rodman & Renshaw, LLC acted as the exclusive placement agent and Merriman Curhan Ford served as a financial advisor to Catalyst with respect to the transaction.
Among the investors in the offering is Federated Kaufmann Funds.
The shares of common stock may only be offered by means of a prospectus. Copies of the final prospectus supplement and accompanying base prospectus can be obtained from the SEC's website at www.sec.gov.
SOURCE Catalyst Pharmaceutical Partners, Inc.